NCT06680752View on ClinicalTrials.gov

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

May 20, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

December 31, 2028

Conditions
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia RefractoryMDS (Myelodysplastic Syndrome)
Interventions
BIOLOGICAL

ARD103

ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion

DRUG

Cyclophosphamide

iv administration for lymphodepletion

DRUG

Fludarabine

iv administration for lymphodepletion

Trial Locations (3)

27201

RECRUITING

Novant Health Cancer Institute, Winston-Salem

28204

RECRUITING

Novant Health Cancer Institute, Charlotte

77030

NOT_YET_RECRUITING

MD Anderson Cancer Center, Houston

Sponsors
All Listed Sponsors
lead

ARCE Therapeutics, Inc.

INDUSTRY

NCT06680752 - Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS | Biotech Hunter | Biotech Hunter